Delek US Holdings Deal Termination with MUFG Bank, Ltd.
Delek US Holdings, Inc. has repaid in full and terminated its Amended and Restated Term Loan Credit Agreement originally dated November 18, 2022. The payoff was funded using cash on hand and proceeds from the company's 0.00% Convertible Senior Notes due 2031, resulting in the release of all related guarantees and liens.
Addentax Group Deal Termination with Double Cash Finance Limited
Addentax Group Corp. and its subsidiary Yingxi Industrial Chain Investment Co., Ltd. mutually agreed to terminate a previously announced share exchange agreement with Double Cash Finance Limited and Mr. Chan Kai Sang. The original deal would have seen Addentax acquire 100% of Double Cash in exchange for 464,907 shares of common stock. No shares were issued, and no termination fees or penalties are payable by any party as a result of the cancellation.
WinVest Acquisition Deal Termination with Embed Financial Group Holdings
Winvest Acquisition Corp. mutually agreed to terminate its previously announced business combination agreement with Embed Financial Group Holdings, effective November 9, 2026. As a result of the termination, the planned merger transactions were abandoned and all related ancillary documents were cancelled. The parties have entered into a mutual release of all claims and liabilities related to the transaction.
Microvision Deal Termination with Redmond East Office Park LLC
MicroVision entered into an agreement with Redmond East Office Park LLC to terminate two property leases in Redmond, Washington, effective November 30, 2026. The termination is expected to reduce the company's future obligations by approximately $12.8 million in exchange for a cash payment of $561,973 and the forfeiture of a $915,775 security deposit.
Microvision Deal Termination with Redmond East Office Park LLC
MicroVision entered into a termination agreement with Redmond East Office Park LLC to exit two leases in Redmond, Washington, effective November 30, 2026. The company will pay approximately $1.48 million in cash and forfeited security deposits to eliminate approximately $12.8 million in future lease obligations. Additionally, the company reported that its outstanding senior secured convertible notes have been reduced by nearly 80% to $7.8 million.
Nano Dimension Deal Termination with Stratasys Ltd.
Nano Dimension and Stratasys have mutually agreed to terminate the previously announced $42.5 million sale of Nano Dimension's subsidiary, MarkForged, Inc. The parties determined that obtaining the necessary regulatory approvals would take significantly longer and be more costly than initially expected.
Western Union Deal Termination with International Money Express, Inc.
Western Union terminated its definitive merger agreement to acquire International Money Express (Intermex) after failing to reach acceptable terms with California's Department of Financial Protection and Innovation (DFPI). The regulator imposed conditions that would have required material changes to Western Union's business model and agent relationships, which the company deemed not in the best interests of shareholders. No termination fee is payable by either party, though Intermex has reportedly threatened legal action regarding the termination.
International Money Express Deal Termination with The Western Union Company
The Western Union Company has issued a notice to terminate its previously announced merger agreement with International Money Express, Inc. (IMXI) after the deal failed to close by the November 10, 2026, outside date. IMXI has disputed the termination, alleging Western Union breached its obligations to obtain regulatory approvals and is reserving its rights to seek specific performance or damages.
Aptera Motors Deal Termination with Cantor Fitzgerald & Co.
Aptera Motors Corp. has suspended and terminated its prospectus related to an at-the-market (ATM) offering program with Cantor Fitzgerald & Co. The company stated it will not make any further sales under the Sales Agreement until a new prospectus is filed. Additionally, the company provided a preliminary financial update estimating a cash balance of approximately $9.2 million as of September 30, 2026.
Todd Hornbeck, President and CEO of Hornbeck Offshore Services, has terminated a Rule 10b5-1 trading plan originally established on September 1, 2026. The plan was intended for the sale of 1,170,405 shares of common stock, but no shares were sold prior to its cancellation.
21Shares Dogecoin ETF Deal Termination with House of Doge Inc.
21Shares US LLC, the sponsor of the 21Shares Dogecoin ETF, has terminated its Support Services Agreement with House of Doge Inc. effective immediately. The agreement covered research, data, operational support, and marketing services provided to the Trust.
Beam Global and the shareholders of ScoutDI AS have mutually terminated their previously announced Share Sale and Purchase Agreement dated October 6, 2026. The deal was cancelled due to unfavorable conditions in the U.S. public markets after the closing did not occur by the November 4, 2026 deadline. No cash consideration will be paid and no shares will be issued, though the companies intend to explore alternative manufacturing and distribution partnerships.
StartEngine Inc. has terminated its Regulation A equity offering (SEC File No. 024-12778). The company reported that no securities were issued or sold under this offering prior to its cancellation.
Grant Park Futures Fund Limited Partnership Deal Termination with Episteme Capital Partners LLP
Grant Park Futures Fund Limited Partnership has terminated its advisory contract with Commodity Trading Advisor (CTA) Episteme Capital Partners (UK) LLP, effective November 1, 2026. Episteme previously managed approximately 20% of the Fund's net assets, which will now be reallocated among the Fund's existing CTAs: EMC Capital Advisors, Quantica Capital, and Sterling Partners Quantitative Investments.
Korro Bio received notice from Novo Nordisk of its election to terminate their 2024 research collaboration and license agreement for convenience, effective February 1, 2027. The partnership, which focused on cardiometabolic targets, had been paused since November 2025 and will now conclude with all licenses terminated and no milestone payments earned.
Counterparty
Novo Nordisk A/S
“Initiating dosing in ANCHOR brings KRRO-121 a meaningful step closer to these patients, and we look forward to dosing participants with UCDs in the first half of 2027. In AATD, our preclinical data showing over 95% correction of the disease-causing transcripts gives us confidence as we prepare KRRO-111 for the clinic. Both programs reflect what our OPERA platform is intended to do: correct disease at the level of RNA, with the precision to generate the protein of interest and convenience of subcutaneous administration. We are focused on execution, with two GalNAc-delivered RNA-editing programs advancing toward clinical data, and a cash runway into the second half of 2028.”
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio
DataMeds AI Deal Termination with EOS Technology Holdings, Inc.
DataMEDS AI, Inc. has terminated its Second Amended and Restated Letter of Intent (LOI) with multiple parties including EOS Technology Holdings, Scilex, and Datavault AI. The LOI contemplated the acquisition of intellectual property assets and a controlling interest in Tollo Health in exchange for common stock, but was cancelled due to market conditions. The company stated that no shares will be issued and no fees are owed as a result of the termination.
Matinas BioPharma Holdings, Inc. has terminated its agreement with a former financial advisor, which previously entitled the advisor to up to $4.0 million in cash and stock for business combinations. In connection with the termination, the company paid the advisor $562,500 in cash and exchanged mutual releases. This action removes potential future success-fee obligations related to strategic transactions.
Nurix Therapeutics Deal Termination with Sanofi S.A.
Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.
Rising Dragon Acquisition Deal Termination with HZJL Cayman Limited
Rising Dragon Acquisition Corp. and HZJL Cayman Limited have mutually agreed to terminate their previously announced merger agreement, effective October 30, 2026. The termination agreement includes mutual releases and does not require any party to pay a termination fee. Rising Dragon intends to continue seeking an alternative initial business combination within its permitted timeframe.
THC Therapeutics Deal Termination with ST Holdings Group, LLC
THC Therapeutics and ST Holdings Group, LLC mutually agreed to terminate their previously announced Share Exchange Agreement due to accounting complexities. While the merger agreement is cancelled, the parties are currently exploring alternative options for a potential future acquisition of some or all of ST Holdings' assets.
Creatd Deal Termination with C2 Capital Group, Inc.
Creatd, Inc. and C2 Capital Group, Inc. (C2 Live) mutually agreed to terminate a binding letter of intent for Creatd to acquire the remaining equity of C2 Live. The transaction will not be consummated, and Creatd incurred no early termination penalties, though it retains its existing 10% investment in the counterparty.
Allarity Therapeutics Deal Termination with Tumim Stone Capital LLC
Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital, effective October 28, 2026. The agreement had allowed the company to sell up to $6.0 million of common stock at its discretion, but Allarity elected to cancel the facility to pursue alternative financing arrangements. No early termination penalties were incurred as a result of the cancellation.
Olenox Industries entered into a mutual termination agreement to cancel its $100 million equity line of credit (ELOC) purchase agreement and related registration rights agreement. No shares were sold under the facility prior to termination, and the company will issue 298,604 shares of common stock to the investor as a termination fee. The company must issue additional shares if the value of the termination shares is less than $258,440 based on a future 10-day VWAP.
Prothena Corp Public Ltd Deal Termination with Bristol Myers Squibb
Bristol Myers Squibb (BMS) has terminated its exclusive global license agreement for PRX019 with Prothena following an internal strategic review. As a result of the termination, effective January 28, 2027, Prothena is no longer eligible to receive up to $617.5 million in potential development, regulatory, and sales milestones. BMS will continue to develop moponetug (PRX005) under a separate ongoing collaboration agreement.
First Breach Deal Termination with ideaForge Technology Inc.
First Breach Inc. and ideaForge Technology Inc. mutually agreed to terminate their Joint Venture Agreement originally established to manufacture and distribute unmanned aerial vehicles in the U.S. As a result, First Breach is no longer obligated to make a planned $25 million capital contribution, including a $10 million tranche due in December 2026. The company intends to continue its drone program independently and through its existing partnership with Hellbender, Inc.
Ecominas Deal Termination with Francisco Antonio Sbert Mousko
Ecominas Corp. terminated and rescinded its Asset Purchase Agreement with Francisco Antonio Sbert Mousko due to the seller's breach and repudiation. The company will no longer acquire the technology and real-property assets and has cancelled the planned issuance of 700,000 Series A Preferred shares. Additionally, the board approved a corporate name change to EcoCora Intelligence Corp., pending shareholder and regulatory approval.
Supernus Pharmaceuticals Deal Termination with UBS Bank USA
Supernus Pharmaceuticals terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The termination was made in anticipation of the company's pending merger with Indivior Pharmaceuticals and the establishment of a new senior secured credit facility for the combined entity. There were no outstanding borrowings or early termination penalties associated with the cancellation.
Azitra Deal Termination with A.G.P./Alliance Global Partners
Azitra, Inc. announced it has decided to suspend and not utilize its at-the-market (ATM) offering program with A.G.P./Alliance Global Partners for the foreseeable future. The company cited its current capital resources, upcoming milestones, and the dilutive effect of equity issuances as reasons for the decision. Separately, the company released positive ex vivo study data for its ATR-COSF cosmetic program showing improvements in skin elasticity and fine lines.
HyOrc Deal Termination with ONENERGY GREENPOWER EAD and ON ENERGY EOOD
HyOrc Corporation received a notice from OnEnergy purporting to terminate their March 2026 agreement regarding a waste-to-methanol project in Bulgaria following a failed joint grant application. HyOrc is formally disputing the validity of the termination, claiming the contractual conditions for such an action have not been met, and has reserved its intellectual property rights.
Belpointe PREP Deal Termination with 100 Tokeneke Road, LLC
Belpointe PREP's subsidiary BPOZ Tokeneke received a full prepayment of $5.11 million for a convertible promissory note from 100 Tokeneke Road, LLC. The prepayment effectively terminates the material definitive agreement and the company's right to convert the debt into equity of Tokeneke Partners. The transaction was approved by the company's Conflicts Committee as the counterparty is managed by an entity controlled by Belpointe's CEO.